This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages without signing in

IMPRESS trial

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Omapatrilat inhibits:

  • angiotensinogen converting enzyme, resulting in reduced vasoconstriction and renin activation
  • neutral endopeptidas,e resulting in elevated vasodilatory peptide concentrations

Omapatrilat was compared to lisinopril in 573 patients with NYHA grade II-IV heart failure. The patients had all required ACE inhibitor therapy prior to the trial.

Target doses were:

  • 40 mg omapatrilat per day
  • 20 mg lisinopril per day

Follow-up was 24 weeks.

The primary endpoint was exercise tolerance measured by a treadmill test at 12 weeks. Secondary endpoints included death, admission or discontinuation of treatment because of worsening heart failure.

Reference:

  • (1) Rouleau, JL, Pfeffer , MA. et al. (2000). Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet, 356, 615-20.

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.